Lumos Pharma Announces Abstract Accepted For Oral Presentation At The 13th Biennial Scientific Meeting Of The Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma Announces Abstract Accepted For Oral Presentation At The 13th Biennial Scientific Meeting Of The Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.
Lumos Pharma，Inc.（納斯達克：LUMO），一家臨床階段的生物製藥公司，專注於罕見疾病的治療藥物，今天宣佈其OraGrowtH210臨床試驗階段2數據的更新分析已被接受，將在2024年10月2日至5日在印度新德里舉行的第13屆亞太兒科內分泌學會議（或APPES 2024）上進行報告。這項針對口服LUm-201治療兒童生長激素缺乏症（PGHD）的OraGrowtH210試驗數據分析，將由新西蘭奧克蘭大學理金斯學院的Paul Hofman教授於10月3日進行報告。
Abstract Presentation: Thursday, October 3rd – Oral Session: Growth & Puberty – 2:30PM Local Time
摘要報告：週四，10月3日－口頭報告：生長與青春期－當地時間下午2:30
- Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofman, MD, et al)
- 題爲《兒童生長激素缺乏症（PGHD）中口服生長激素（GH）促分泌物LUm-201對生長、IGF-1和IGFBP-3的反應》的摘要，來自OraGrowtH210試驗（Paul Hofman，MD，等人）
譯文內容由第三人軟體翻譯。
